healthcare – Page 2 – Market Industry Forecast News

Therapeutic Drug Monitoring Market Challenges: Overcoming Data Management Issues

The global therapeutic drug monitoring market size is estimated to reach USD 2.32 billion by 2030, expanding at a CAGR of 3.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. Recent technological advancements in the Point-of-Care (PoC) devices hold considerable transformative promises for the personalized predictive and preventive medicine. Therapeutic Drug Monitoring (TDM) forms a foundational part to the devising of personalized treatment plans for patients; and the advent of PoC diagnostic devices that yield quantitative measurements of the drug concentration plays a pivotal role in supporting the development of the precision medicine field in the healthcare sector. However, the broad application of the PoC devices for patient monitoring is still lagging behind. The presence of this untapped opportunity is one of the high impact rendering drivers for the market growth.

The employment of continuous therapeutic drug and metabolite monitoring in the early phase of the medication regimen, administered post-organ transplantation, forms a major application in the areas of critical care medicine and organ transplantation, which is expected to propel the growth of the therapeutic drug monitoring market over the forecast period. In addition, the imposing burden of diseases, such as epilepsy and cancer, the rising government initiatives, and the presence of high-unmet needs are some of the crucial determinants expected to further favor the emergence of this market.

Access the Therapeutic Drug Monitoring Market Size, Share & Trends Analysis Report By Product (Equipment, Consumables), By Drug Class (Antiarrhythmic Drugs), By End Use (Diagnostic Centers), By Region, And Segment Forecasts, 2024 – 2030

Therapeutic Drug Monitoring Market Report Highlights

The consumables segment covered over 65.4% of the market share in 2023 as a consequence of the extensive requirement of the consumables in the research laboratories and due to the repeat purchase of the kits and reagents.

The immunosuppressants segment is expected to grow fastest, with a compounded annual growth rate of 5.3% over the forecast period.

The hospital segment dominated the market share in 2023. In larger hospitals, various underlying technologies are employed to perform immunoassays; these comprise chemiluminescence, nephelometry, colorimetry, and fluorescence, which are available for the testing of a wide ranging drug panel.

The drug monitoring for the immunosuppressants is one of the fastest growing application segments owing to the introduction of novel TDM point-of-care testing devices for the evaluation of the concentration of administered immunosuppressants and the complementary metabolites, in order to achieve a prominent therapeutic effect while preventing drug toxicity events in patients that have undergone transplantations.

Key Therapeutic Drug Monitoring Company Insights

Some of the key companies in the therapeutic drug monitoring market are Abbott, ALPCO, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Chromsystems Instruments & Chemicals GmbH, F.Hoffmann-La Roche Ltd., Randox laboratories Ltd, Siemens Healthineers AG., and biomérieux, Inc. Organizations are focusing on increasing customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions and partnerships with other major companies.

Abbott, known for its diagnostic technologies, offers a range of products and solutions tailored to monitor drug levels in patients effectively. These include assays and instruments that aid healthcare providers in optimizing medication dosages, ensuring efficacy, and enhancing patient safety across various therapeutic areas.

ALPCO (American Laboratory Products Company) is a player in the therapeutic drug monitoring market, specializing in providing high-quality assays and immunoassay kits. These products are designed to accurately measure drug levels in patient samples, supporting healthcare providers in optimizing therapeutic outcomes and patient management.

Order your free sample copy of “Therapeutic Drug Monitoring Market Report 2024 – 2030, published by Grand View Research

Key Therapeutic Drug Monitoring Companies:

The following are the leading companies in the therapeutic drug monitoring market. These companies collectively hold the largest market share and dictate industry trends.

Abbott
ALPCO
Beckman Coulter, Inc
Bio-Rad Laboratories, Inc
Thermo Fisher Scientific Inc.
Chromsystems Instruments & Chemicals GmbH
F.Hoffmann-La Roche Ltd.
Randox laboratories Ltd
Siemens Healthineers AG.
biomérieux, Inc.

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Heart Attack Diagnostics Market Challenges: Addressing Barriers to Effective Diagnosis

The global heart attack diagnostics market size is expected to reach USD 18.52 billion by 2030, according to a new report by Grand View Research, Inc. The heart attack diagnostics market is anticipated to grow at a CAGR of 8.2% during the forecast year from 2024 to 2030. The overall risk factors and the disease burden remains large, thereby rendering the heart attack diagnostic sectors a profitable growth prospect. This growth is attributed to a majority of factors, such as high prevalence of coronary heart diseases, increased tobacco smoking, and obesity, enhanced adoption of unhealthy diet is resulting in a high cholesterol incidence in individuals, particularly in the rising geriatric population. However, the low Medicare reimbursement provided for the mobile cardiac outpatient telemetry electrocardiogram (ECG) and the progressively declining heart attack incidence rates are expected to hamper the market growth.

Access the Heart Attack Diagnostics Market Size, Share & Trends Analysis Report By Test (Electrocardiogram, Blood Test), By End-use (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2024 – 2030

The heart attack diagnostics market has been classified by product into electrocardiogram, which measures the electrical activity of the heart; echocardiogram, a form of ultrasound test that provides images of the heart; blood tests that measure the expression of certain proteins in excess, such as troponin levels, and cardiac enzymes; and other diagnostic products. The ECG segment is expected to witness a significant growth rate in developing countries, owing to the technological advances coupled with increasing applications of ECG. Although, the increasing demand for cost effective, rapid blood tests such as troponin and Creatine Kinase MB Isoenzyme (CK-MB) is likely to acquire major market share in the near future. The key countries landscape included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and Middle East. The Asia Pacific region is anticipated to be the fastest growing region during the forecast period. On the other hand, North America is estimated to dominate the global heart attack diagnostics market.

Heart Attack Diagnostics Market Report Highlights

North America is estimated to dominate the global heart attack diagnostics market. The increasing awareness about heart attacks, its causative and risk factors, and enhanced uptake and acceptance of technologically advanced diagnostics is expected to contribute to the market growth.

The Asia Pacific region is expected to be the fastest growing region during the forecast period. to The reason being the considerably large burden of heart diseases in certain developing regions, such as in India, where 2.4 million people die annually due to heart diseases. As a result of the soaring incidences of heart diseases, an urgent requirement to undertake awareness measures and incorporate advanced diagnostics is expected to fuel the market growth.

The Troponin segment dominated the blood tests market and accounted for a share of 62.5% in 2023. Troponin T, a protein present in the heart muscle, is crucial in diagnosing heart attacks through a high-sensitivity troponin T test.

Key Heart Attack Diagnostics Company Insights

The surge in competition is driving rapid technological progress, prompting companies to enhance their products through extensive research and development efforts. Leading companies are adopting various strategic approaches like mergers & acquisitions, partnerships, and new product introductions to increase their market presence.

Order your free sample copy of “Heart Attack Diagnostics Market Report 2024 – 2030, published by Grand View Research

Key Heart Attack Diagnostics Companies:

The following are the leading companies in the heart attack diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

GE Healthcare
Hitachi Corporation
Koninklijke Philips NV
Midmark Corporation
F Hoffmann-La Roche Ltd
Schiller AG
Siemens Healthineers
Toshiba Corporation
Welch Allyn Inc
Astrazenca PLC

Recent Developments

In June 2024, Philips announced the launch of Philips Cardiac Workstation aims to transform diagnostic cardiology with introduction of new Cardiac Workstation, to enhance cardiology patients care and accelerate clinical decision making in Middle East and Africa (MEA) and Europe
In April 2024, GE Healthcare introduced Caption AI on Vscan Air SL to expand cardiac care access by allowing more clinicians/medical professional capture diagnostic-quality cardiac images.

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Fabry Disease Treatment Market Research: Key Findings on Drug Development and Usage

The global fabry disease treatment market size is estimated to reach a value of USD 4.93 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.9% from 2024 to 2030. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market.

Fabry disease is a rare inherited lysosomal storage disorder caused by genetic mutation that interferes with function of alpha galactosidase enzyme. Fabry disease generally has a late onset with mild symptoms, due to which several patients are often undiagnosed. Standard of care for management of the disease is enzyme replacement therapy (ERT). Sanofi’s Fabrazyme and Shire’s Replagal are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has been approved.

Access the Fabry Disease Treatment Market Size, Share & Trends Analysis Report By Solution, By Treatment (Enzyme Replacement Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

Focus of current clinical trials is to improve the safety and efficacy profile of ERTs and introduction of novel oral therapies that can eliminate the need for intravenous infusions. Recently, Amicus Therapeutics’ Galafold has been approved as the first oral chaperone therapy for the treatment of adults in the U.S., Canada, EU, Japan, Australia, Israel, and South Korea.

North America held the largest share in the Fabry disease treatment market in 2017, followed by Europe. The growth of the region can be attributed to higher adoption of novel therapies, favorable reimbursement policies, and better healthcare facilities. However, high cost of therapy with ERTs such as Fabrazyme is an impediment for the market in developing regions.

Fabry Disease Treatment Market Report Highlights

Intravenous route dominated the market with a market share of 65.9 % in 2023 and is also expected to grow at the fastest CAGR over the forecast period from 2024 to 2030.

The enzyme replacement treatment segment dominated the market and accounted for a share of 72.3 % in 2023.

North America commanded the leading market share of more than 45.1% in the Fabry disease treatment market, followed by Europe, in 2023

APAC is likely to witness the fastest growth during the forecast period, followed by Latin America, due to increasing healthcare expenditure and rising patient population

Order your free sample copy of “Fabry Disease Treatment Market Report 2024 – 2030, published by Grand View Research

Key Fabry Disease Treatment Company Insights

Some of the key companies in the fabry disease treatment market include Sanofi S.A.; Shire PIc.; Amicus Therapeutics Inc.; ISU Abxis Co Ltd.;J CR Pharmaceuticals Co Ltd.; Protalix Biotherapeutics Inc.; and Idorsia Pharmaceuticals Ltd. The participants are involved in tactical strategy formation, creation of new treatments, and agreements aimed at achieving broad expansion and securing the top spot in the industry.

Sanofi S.A. healthcare companies are a culmination of a diverse group of companies collaborating on healthcare innovation. Also develops various treatments to treat numerous uncommon illnesses such as Fabry diseases. Amicus Therapeutics is a company that makes medicine for people with rare diseases. Amicus Therapeutics is focused on developing and expanding a pipeline of cutting-edge medicines for rare diseases such as fabry disease.

Key Fabry Disease Treatment Companies:

The following are the leading companies in the fabry disease treatment market. These companies collectively hold the largest market share and dictate industry trends.

Sanofi S.A.
Shire PIc.
Amicus Therapeutics Inc.
ISU Abxis Co Ltd.
JCR Pharmaceuticals Co Ltd.
Protalix Biotherapeutics Inc.
Idorsia Pharmaceuticals Ltd.
Avrobio Inc.
Takeda Pharmkceutical Co Ltd.
Chiesi Farmaceutici SpA
Freeline Therapeutics Holdings PLC
Yuhan Corp
MOP Therapeutics

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Anterior Uveitis Treatment Market Demand Rises with New Drugs

The global anterior uveitis treatment market size is expected to reach USD 967.5 million by 2030, registering a CAGR of 12.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of the disease is anticipated to aid market growth. This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.

According to a 2017 article by Retina Today, this condition accounted for around 30% to 90% of the cases of uveitis. It also stated around 1% to 4% of patients experience 25% loss of visual acuity. There are different effective treatments for this disease and can be easily managed; however, it tends to recur. This disease is prevalent among both young and middle-aged group. It is also common among the geriatric population. Ocular ischemia and herpetic uveitis are the two most common causes of this disease among the geriatric population. Most of the cases occur in healthy people, however, some are associated with infectious diseases, gastrointestinal disorders, rheumatologic diseases, and lung & skin diseases. This disease is less sight-threatening as compared to posterior uveitis, however, in some cases might lead to glaucoma, cataract, and cystoid macular edema.

Access the Anterior Uveitis Treatment Market Size, Share & Trends Analysis Report By Type (Infectious Uveitis), By Therapy (Biologics), By Distribution Channel (Hospital, Retail, Online Pharmacies), By Region, And Segment Forecasts, 2024 – 2030

Anterior Uveitis Treatment Market Report Highlights

Corticosteroids dominated the anterior uveitis treatment market in 2023 owing to its beneficial characteristic of minimizing inflammation in the eye. It is the primary treatment modality.

Anti-TNF agents are expected to exhibit lucrative growth rate over the forecast period due to growing opportunity in treatment methods with biologic therapy using Anti-TNF drugs.

Immunosuppressants held a significant market share in 2023 owing to their growing adoption for treatment of chronic anterior uveitis.

Hospital pharmacies dominated the market in 2023 due to the wide treatment options available there.

Online pharmacies are expected to witness significant CAGR over the forecast period due to convenience, ease, and availability of discounted products.

North America held the largest revenue share in 2023 owing to high prevalence as well as healthcare expenditure in this region.

Asia Pacific is anticipated to exhibit lucrative growth during the forecast period due to the rising number of infectious diseases in developing countries of the region and growing disposable income.

Order your free sample copy of “Anterior Uveitis Treatment Market Report 2024 – 2030, published by Grand View Research

Key Anterior Uveitis Treatment Company Insights

Some of the key companies in the Anterior Uveitis Treatment market include Novartis AG, Santen Pharmaceutical Co., Ltd., AbbVie Inc., Kiora Pharmaceuticals, Inc., Clearside Biomedical, Aldeyra Therapeutics, Inc., UCB S.A., Agilent Technologies, Inc. (Lux Biosciences, Inc)., Tarsier Pharma Ltd. Key manufacturers are increasingly adopting strategic initiatives such as new product development, mergers & acquisitions, and regional expansion. For instance, in 2024, Kiora Pharmaceuticals, Inc. announced the results from phase I clinical trial of KIO-101 and plans for phase II clinical trial of KIO-104 for intravitreal delivery into the retina for treating posterior non-infectious uveitis.

AbbVie Inc. is actively functioning in the eye care segment. It has a wide range of products to treat various ophthalmic conditions. One of the prime products of the company for treating uveitis is “Humira” which is widely accepted as an effective treatment worldwide.
Kiora Pharmaceuticals, Inc. is exclusively involved in developing therapies for inherited and inflammatory retinal diseases. There are advanced products present in their pipeline to treat anterior uveitis.

Key Anterior Uveitis Treatment Companies:

The following are the leading companies in the anterior uveitis treatment market. These companies collectively hold the largest market share and dictate industry trends.

Novartis AG
Santen Pharmaceutical Co., Ltd.
AbbVie Inc.
Kiora Pharmaceuticals, Inc.
Clearside Biomedical
Aldeyra Therapeutics, Inc.
Aciont Inc.
Sirion Therapeutics, Inc.
UCB S.A.
Lux Biosciences, Inc.
Tarsier Pharma Ltd.

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Osteoporosis Drugs Market: Key Players Shaping the Future Landscape

The global osteoporosis drugs market size is expected to reach USD 18.80 billion by 2030 and is projected to grow at a CAGR of 3.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Access the Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

Osteoporosis Drugs Market Report Highlights

Branded drugs held the dominant share of the product segment in 2023. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy

Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies

In 2023, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics

Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care

The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Order your free sample copy of “Osteoporosis Drugs Market Report 2024 – 2030, published by Grand View Research

Key Osteoporosis Drugs Company Insights

Some key companies in the osteoporosis drugs market include Amgen Inc; Eli Lilly and Company; Merck & Co., Inc.; Novartis AG; GlaxoSmithKline plc; Pfizer Inc.; Radius Health Inc.; UCB S. A.; Teva Pharmaceuticals Industries Ltd. in the market are focusing on the development of osteoporosis drugs to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives.

Amgen Inc. develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicine for treating cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders, and nephrology conditions.

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent-protected prescription medicines, generic pharmaceuticals, and biosimilars.

Key Osteoporosis Drugs Companies:

The following are the leading companies in the osteoporosis drugs market. These companies collectively hold the largest market share and dictate industry trends.

Amgen Inc.
Eli Lilly and Company
Merck & Co., Inc.
Novartis International AG
Pfizer Inc.
GlaxoSmithKline plc
Radius Health, Inc.
UCB S.A.
Teva Pharmaceutical Industries Ltd.
Roche Holding AG

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Hydrogel-based Drug Delivery System Market Key Insights: Navigating Emerging Trends

The global hydrogel-based drug delivery system market size is anticipated to reach USD 11.77 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.7% from 2024 to 2030. Hydrogels help in achieving spatial and temporal control over the release of the incorporated drug. Therefore, the surging demand for controlled releases drug delivery system across many therapeutic areas is a key factor expected to contribute to market growth during the forecast period.

Hydrogel-based drug delivery systems deliver the therapeutic drug directly at the target site and in a sustained manner. This can leverage beneficial outcomes such as improved efficacy, reduced side effects, and decreased dosage for patients and formulators. Hydrogel-based drug delivery systems are appealing and have been used in many branches of medicine such as oncology, pain management, immunology, cardiology, and wound management.

Access the Hydrogel-based Drug Delivery System Market Size, Share & Trends Analysis Report By Polymer Origin (Natural, Synthetic, Hybrid), By Delivery Route, By Region, And Segment Forecast, 2024 – 2030

The unique physical properties of hydrogel attract their interest in use for drug delivery applications. The porosity and drug loading capacity of hydrogels can be adjusted by modifying the density of cross-linking. This helps them to protect liable large drug molecules from degradation increasing the half-life. Many research studies have been carried out to examining the delivery of insulin orally using hydrogel systems. As patient compliance issues are frequently reported with injectable insulins such innovation is expected to be a disruptive technology in the diabetes care market.

There are numerous clinical studies underway specific to hydrogel-based drug delivery systems and various hydrogel technologies have already received regulatory approval for biomedical application. However, the technological challenges including the absence of defined regulatory guidelines, chemistry, complex manufacturing and control paraments, and practical adaptability are major roadblocks in the successful implementation in drug delivery use. For instance, the fabrication of hydrogel is complex and varies significantly depending upon the hydrogel systems.

Hydrogel-based Drug Delivery System Market Report Highlights

Based on polymer origin, the synthetic segment held the largest proportion of market share in 2023

The hybrid segment is expected to witness the fastest growth rate over the forecast period owing to the development of stimuli-responsive hydrogel technology

The synthetic segment is anticipated to grow fast over the forecast period compared to natural hydrogels due to their high drug loading capacity and improved mechanical strength

Based on delivery route, the ocular segment accounted for the largest revenue share in 2023

The subcutaneous segment is expected to grow at a healthy rate over the forecast period owing to the increasing number of clinical and pre-clinical studies carried out

North America holds the largest revenue share in this market due to the presence of key companies in the region doing R&D on specific hydrogel-based drug delivery systems

In Asia Pacific, the market is expected to grow at the fastest rate over the forecast period due to large patient base, improving healthcare infrastructure, and surging demand for modern therapies

Order your free sample copy of “Hydrogel-based Drug Delivery System Market Report 2024 – 2030, published by Grand View Research

Key Hydrogel-based Drug Based Delivery System Company Insights

Some key companies in the market include GALDERMA; Blairex Laboratories, Inc.; Johnson & Johnson; Bausch + Lomb; Medtronic; and Ocular Therapeutix, Inc. Vendors in the market are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other emerging and prominent industry participants.

Ocular Therapeutix, Inc., is a biopharmaceutical company that specializes in creating, advancing, and marketing new treatments for eye disorders. It employs its own bioresorbable hydrogel-based formulation technology, ELUTYX. The company has manufacturing facilities in Massachusetts.

Blairex Laboratories, Inc., a global pharmaceutical company, delivers products related to the consumer and pharmaceutical industry. Some of the company’s major offerings are sterile saline solutions and contact lens care.

Key Hydrogel-based Drug Delivery System Companies:

The following are the leading companies in the hydrogel-based drug delivery system market. These companies collectively hold the largest market share and dictate industry trends.

GALDERMA
Blairex Laboratories, Inc
Johnson & Johnson
Bausch + Lomb.
Medtronic
Ocular Therapeutix, Inc.
Ferring B.V.
Endo, Inc.
Tolmar Inc

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Buttock Augmentation Market Key Insights: Navigating Emerging Trends

The global buttock augmentation market size is anticipated to reach USD 11.72 billion by 2030, according to the new report of Grand View Research, Inc. The market is expected to expand at a CAGR of 21.5% from 2024 to 2030. Buttock augmentation also called gluteal augmentation is a technique used to contour, size, and enhance the appearance. A buttock lift is reported to improve the tone of the underlying tissue and is mainly done by using implants, fat grafting, or sometimes a combination of the two.

Factors like rising technological advancement in aesthetics, rising disposable income, increasing aesthetic consciousness and the high success rate of augmentation procedures are propelling the market growth. According to the International Society of Aesthetic Plastic Surgery, around 5, 34,345 butt augmentation and lift procedures were carried out globally in 2019. Buttock augmentation accounts for 4.7% of total surgical procedures globally.

Access the Buttock Augmentation Market Size, Share & Trends Analysis Report By Procedure (Buttock Implants, Buttock Injections), By End-use (Hospitals, Aesthetic Clinics), By Region, And Segment Forecasts, 2024 – 2030

Growing social media influence, high consciousness towards aesthetic appearance, and its association with self-confidence and self-image by an individual are some of the reasons for market growth. In the light of COVID-19, the market was hampered as patient appointments for surgical treatments were temporarily suspended. However, since the government in many countries has allowed resuming elective surgical procedures, clinics have also started buttock lift and grafting procedures again. Moreover, according to the BBC network, inquiries and appointments for many surgical and non-surgical cosmetic treatments have seen a surge following the pandemic and are thus expected to propel market growth.

Buttock Augmentation Market Report Highlights

By procedure, the buttock implant procedure segment held the largest revenue share in 2023 as techniques like fat grafting and butt lift are more in demand and has faster post-operative healing

Based on implant type, the fat grafting segment accounted for the largest revenue share in 2023 as this procedure is less complicated, takes less operative time, and has more success rate

In North America, the market accounted for the largest revenue share in 2023 as the region has a high awareness of such procedure and there is high availability of aesthetic professionals

In Asia Pacific, the market is expected to grow significantly in the forecast period owing to technological advancements and an increase in patients opting for procedures to improve aesthetic appearances

Order your free sample copy of “Buttock Augmentation Market Report 2024 – 2030, published by Grand View Research

Key Buttock Augmentation Company Insights

Some of the companies key companies in global buttock augmentation market are Abbvie (AllerganAesthetics), GC Aesthetics, Sebbin, and other. To develop a competitive edge over others, the key companies have embraced strategies such as innovation.

Allergan Aesthetics, a subsidiary of the global pharmaceutical organization AbbiVie, develops, manufactures, and distributes offerings related to body contouring, facial injectables, skin care, and plastics. The company also invests heavily in research and development activities to deliver innovation-backed products. It is headquartered in Irvine, California, and has several manufacturing sites across multiple locations around the world.

GC Aesthetics, one of the prominent players in aesthetic enhancements and pre & post-surgery solutions, primarily delivers offerings related to breast enhancements, face implants, body implants, and Remote Valve Tissue Expanders (RVTEs).

Key Buttock Augmentation Companies:

The following are the leading companies in the buttock augmentation market. These companies collectively hold the largest market share and dictate industry trends.

Abbvie. (AllerganAesthetics)
Dermax Co. Ltd.
GC Aesthetics
Implantech
Sientra Inc.
Sebbin
Merz Pharma
Alpha Aesthetics
Hanson Medical Inc.
GALDERMA 2024
CGBio

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Dental Implants Market: Innovations in Materials and Techniques Transforming Care

The global dental implants market size is expected to reach USD 9.62 billion by 2030, registering a CAGR of 9.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising demand for tooth replacement has provided good growth potential to the market. The increasing number of dental injuries owing to road accidents and sports injuries are some of the major factors boosting the market growth.

With growing aesthetic awareness, people are exploring more treatment options, which is leading to the growth of the market. For instance, as per the American Academy of Cosmetic Dentistry data, more than 95.0% of individuals across the globe believe that their smile is a vital social asset and nearly 84.0% revealed to be under increased pressure to perfect their smile, thus increasing the product demand. Dental implants are considered the only restorative technique that preserves and stimulates natural bone. Owing to the growing number of edentulous people, the demand for prosthetics is increasing, which is expected to be one of the major impact-rendering drivers for the market.

Access the Dental Implants Market Size, Share & Trends Analysis Report By Implant Type (Zirconium, Titanium), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2024 – 2030

Several industries have halted their services due to the COVID-19 pandemic. However, the dental care industry is greatly impacted by the significant decrease in elective procedures, many of which are being postponed or canceled so that hospitals can focus their resources on treating patients with COVID-19. Major Countries like the U.S and India procure raw materials and electronic components from China, which has disrupted the supply chain of many dental equipments and product manufacturers. However, with the decrease in the number of COVID-19 cases, hospitals are likely to begin scheduling elective procedures, depending on their capacity of admission and patients comfort level.

Dental Implants Market Report Highlights

The titanium segment held the largest share of more than 91.36% of the overall revenue in 2023 due to its wide applications, durability, and cost-effectiveness

The zirconium segment is anticipated to be the fastest-growing product segment over the forecast period due to better flexural strength, improved aesthetic appearance, and less corrosiveness as compared to titanium

North America dominated the global dental implants market and accounted for the maximum share of more than 35.64% in 2023 owing to high awareness about restorative treatments and the presence of established market players

Order your free sample copy of “Dental Implants Market Report 2024 – 2030, published by Grand View Research

Key Companies & Market Share Insights

Companies are focusing on strategic initiatives, such as the introduction of novel products through customization according to consumers’ needs, partnerships, collaborations, and mergers & acquisitions, to expand their product portfolio and extend leadership positions in the field of dental implantology. Moreover, the competition between key players will turn intense in the coming years as they are focusing more on geographical expansion, strategic collaborations, and partnerships through mergers & acquisitions. In May 2020, Straumann Group announced a new zygomatic implant solution for patients with severe jawbone loss in collaboration with Southern Implants. The new solution combines proven implant design features with the advantages of Straumann’s BLX and BLT implant prosthetic range.

Key Dental Implants Companies:

BioHorizons IPH, Inc.
Nobel Biocare Services AG
Zimmer Biomet Holdings, Inc.
OSSTEM IMPLANT
Institut Straumann AG
Bicon, LLC
Leader Italy
Anthogyr SAS
DENTIS
DENTSPLY Sirona
DENTIUM Co., Ltd.
T-Plus Implant Tech. Co.
KYOCERA Medical Corp.

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

5G Services Market Revolutionizing the Mining Industry with Automated and Remotely Operated Equipment

5G is here! and the world is revolving around the 5G services market to grab the opportunity and align with the market trends. 5G services offer the fastest way to communication and connectivity and help to build the new future.

As the global consumption of high-speed networks rises and the world becomes increasingly reliant on seamless digital experiences, the demand for high-speed, low-latency, and reliable 5G services has skyrocketed.

“5G cell network create a whole new wave of distributed and edge computing” – Micheal Dell, Founder, chairman, and CEO of Dell Technologies

Access the 5G Services Market Size, Share & Trends Analysis Report 2024-2030, published by Grand View Research

While observing global trends, it seems that the 5G has the capacity to turn the wheel for transforming all industries. Understanding the importance of 5G, many global companies across all sectors and governments are taking initiatives to adopt it.

According to Grand View Research estimations, the global market size was USD 84.31 billion in 2023 and will expand at a compound annual growth rate (CAGR) of 59.4% from 2023 to 2030, which can benefit a diverse array of industries that are set to benefit from the 5G revolution.

Types of 5G Communication

This global market is witnessing a remarkable growth trajectory due to the infusion widespread adoption of 5G technology with various communication types such as Fixed Wireless Access (FWA), Ultra-Reliable and Low-Latency Communications (uRLLC), Enhanced Mobile Broadband (eMBB), and Massive Machine-Type Communications (mMTC).

Diversely Adoption of 5G Services

The 5G ecosystem has already started to transform industries such as consumer, manufacturing, healthcare, media and entertainment, public safety, and more. This 5G revolution serves not only consumers but it provides a large number of features by offering solutions for unique requirements.

Order Your Sample Copy of the 5G Services Market Size, Share & Trends Analysis Report by Communication Type (FWA, eMBB, uRLLC, mMTC), By Vertical, By Region, And Segment Forecasts, 2024 – 2030

Trending Industries with 5G Connectivity

Healthcare and Social Work: Post-pandemic, a large transformation is observed as 5G is incorporated into the healthcare industry, enabling remote patient monitoring, telemedicine, and the deployment of advanced medical devices. Similarly, healthcare professionals also adopting 5G to access and share data more efficiently, leading to improved patient outcomes and patient care.

Media and Entertainment: The 5G network’s ability to deliver high-definition video and immersive experiences is revolutionizing the media and entertainment industry. A huge global audience is consuming 5G data to enjoy seamless streaming, live events, and virtual reality (VR) experiences, and therefore, this technology is redefining content consumption.

Manufacturing: 5G’s ultra-low latency and high reliability are revolutionizing the manufacturing sector, designing processes, enabling real-time monitoring, automation, and optimization of production processes. Through 5G, manufacturers can achieve greater efficiency, quality control, and predictive maintenance, ultimately boosting their competitiveness.

Public Safety: In terms of security and public safety, 5G is becoming a game-changer. First responders can leverage 5G-powered solutions for enhanced situational awareness, real-time video streaming, and seamless communication, monitoring & surveillance, improving emergency response times and saving lives.

Energy and Utility: 5G is optimizing the energy and utility sectors such as hydropower plants and renewable energy plants like solar or wind farms, where 5G enables updates through real-time monitoring, predictive maintenance, and smart grid management. Utility companies can leverage 5G to enhance grid resilience, reduce power outages, and improve overall operational efficiency.

Furthermore, the industry list goes on such as IT and Telecom, Transportation and Logistics, Aerospace and Defense, Banking and Finance, Government, Retail, Mining, Oil and Gas, Agriculture, Construction, and Real Estate where 5G offers communication and connectivity.

Summing up

The 5G services market is growing and has a huge potential to reshape the global industries. Nowadays, the way the world lives, works, and communicates has been transformed by the advent of 5G services. As the technology continues to mature and its adoption increases, the world may board into a new era of connectivity, efficiency, and innovation. These new unprecedented advancements in the 5G services market to serve a wide range of industries are creating large opportunities to success in this digital age.

Explore Horizon, the world’s most expansive market research database

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Innovations in Antimicrobial Additives Enhance Hygiene and Safeguard Public Health

Antimicrobial additives have emerged as a crucial technology in consumer products and industrial applications. These additives are designed to inhibit the growth of microorganisms on various surfaces, thereby enhancing product longevity, hygiene standards, and overall safety. As the demand for antimicrobial protection continues to rise across sectors such as healthcare, packaging, textiles, and food processing, the global antimicrobial additives market is experiencing significant growth and evolution.

Antimicrobial additives are substances infused into materials during manufacturing to prevent the growth of bacteria, fungi, algae, and other microbes. They work by disrupting the cellular processes of microorganisms, thereby inhibiting their growth and reproduction. Common antimicrobial agents used in these additives include silver ions, copper ions, zinc pyrithione, quaternary ammonium compounds (QACs), and triclosan, among others.

Access the Antimicrobial Additives Market Size, Share & Trends Analysis Report 2024-2030, published by Grand View Research

Market Drivers

Increasing awareness about the importance of cleanliness and hygiene, especially in healthcare settings and public places, is a significant driver of the antimicrobial additives market. Consumers are more conscious about the transmission of infections and are seeking products that offer antimicrobial protection. Hospitals, clinics, and other healthcare facilities require stringent infection control measures. Antimicrobial additives in medical devices, equipment, and surfaces help in reducing the risk of healthcare-associated infections (HAIs).

In the consumer goods sector, antimicrobial additives are incorporated into products such as textiles, household appliances, and personal care items. The desire for products that stay cleaner and fresher for longer periods is boosting the demand for antimicrobial-treated goods.

Regulatory bodies across the globe are increasingly emphasizing hygiene and safety standards in various industries. This regulatory support encourages manufacturers to incorporate antimicrobial additives into their products to meet compliance requirements.

Challenges of the Antimicrobial Additives Market

Environmental concern is the biggest challenge in the market for antimicrobial additives. Some antimicrobial additives, such as triclosan, have faced scrutiny due to their potential environmental impact and health concerns. Regulatory restrictions and consumer preferences for eco-friendly alternatives pose challenges to the market growth of certain antimicrobial agents.

There is ongoing concern about the development of antimicrobial resistance among microorganisms when exposed to antimicrobial agents over time. This necessitates continuous research and development efforts to innovate new antimicrobial technologies. Moreover, the incorporation of antimicrobial additives can add to the production costs of materials and products. Manufacturers need to balance the benefits of antimicrobial protection with cost-effectiveness to maintain competitiveness in the market.

Order Your Sample Copy of the Antimicrobial Additives Market Size, Share & Trends Analysis Report By Type (Organic, Inorganic), By Application (Plastics, Paints & Coatings, Pulp & Paper), By End-use, By Region, And Segment Forecasts, 2024 – 2030

Global Market Insights

The global antimicrobial additives market stood at USD 3.11 billion in 2023. This is expected to cross USD 5.60 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.0%. The industry is dominated by the Asia Pacific region, which accounted for over 38.0% share of the global revenue in 2023. The regional market is driven by the growth of major industries such as automotive, construction, healthcare, food and beverage, and packaging, among others. The robust manufacturing base of the automotive industry in countries such as China, India, and Japan is expected to boost the demand for antimicrobial additives in the near future.

The North American region also holds a significant share in the antimicrobial additives market due to stringent regulatory standards and high healthcare expenditure. At the same time, increasing consumer awareness regarding hygiene and growing demand in industries such as food processing and packaging are driving market growth in Europe.

Competitive Landscape and Future Outlook

The antimicrobial additives market is highly competitive, with several key players dominating the industry. Companies are focusing on research and development to introduce innovative antimicrobial technologies and expand their product portfolios. Strategic collaborations, mergers, and acquisitions are also prevalent strategies among market players to strengthen their market position. For example, BioCote Ltd. entered into a strategic partnership with Eco Finish in July 2023 to leverage the technology for antimicrobial surfaces in residential & commercial pools, delivering additional safety and protection for swimmers.

NanoBioMatters Industries S.L, RTP Company, BASF SE, Milliken Chemical, Microban International, BioCote Ltd., Clariant AG, Momentive Performance Materials Inc., Life Materials Technologies Ltd., PolyOne Corporation, SteriTouch Limited, Sanitized AG, LyondellBasell Industries Holdings B.V., Dow Inc., Plastics Color Corporation, and Lonza are some of the key companies operating in the global antimicrobial additives market.

The future of the antimicrobial additives industry looks promising with continued advancements in technology and increasing application across various industries. Key trends shaping the market include:

The development of sustainable antimicrobial solutions.
Integration of antimicrobial properties in smart textiles and wearable devices.
The expansion of antimicrobial additives into new application areas.

Although the market faces some challenges, such as environmental concerns and regulatory scrutiny, ongoing innovation and increasing awareness about infection control are expected to drive market growth. As global demand for antimicrobial protection continues to rise, stakeholders across industries are poised to capitalize on the expanding opportunities presented by this dynamic market.

Explore Horizon, the world’s most expansive market research database

About Grand View Research

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com